These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 16240396)

  • 1. The expression pattern of beta-catenin in mesothelial proliferative lesions and its diagnostic utilities.
    Dai Y; Bedrossian CW; Michael CW
    Diagn Cytopathol; 2005 Nov; 33(5):320-4. PubMed ID: 16240396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cadherins, catenins and APC in pleural malignant mesothelioma.
    Abutaily AS; Collins JE; Roche WR
    J Pathol; 2003 Nov; 201(3):355-62. PubMed ID: 14595746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.
    Bassarova AV; Nesland JM; Davidson B
    Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
    Friedman MT; Gentile P; Tarectecan A; Fuchs A
    Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization.
    Afify AM; Stern R; Michael CW
    Diagn Cytopathol; 2005 Mar; 32(3):145-50. PubMed ID: 15690337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclin A and beta-catenin expression in actinic keratosis, Bowen's disease and invasive squamous cell carcinoma of the skin.
    Brasanac D; Boricic I; Todorovic V; Tomanovic N; Radojevic S
    Br J Dermatol; 2005 Dec; 153(6):1166-75. PubMed ID: 16307653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta-catenin expression in benign and malignant pilomatrix neoplasms.
    Hassanein AM; Glanz SM
    Br J Dermatol; 2004 Mar; 150(3):511-6. PubMed ID: 15030335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of E-cadherin and cytoplasmic-nuclear expression of beta-catenin are the most useful immunoprofiles in the diagnosis of solid-pseudopapillary neoplasm of the pancreas.
    Kim MJ; Jang SJ; Yu E
    Hum Pathol; 2008 Feb; 39(2):251-8. PubMed ID: 17959228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. β-catenin expression in benign and malignant pleural disorders.
    Anani W; Bruggeman R; Zander DS
    Int J Clin Exp Pathol; 2011; 4(8):742-7. PubMed ID: 22135721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions.
    Hasteh F; Lin GY; Weidner N; Michael CW
    Cancer Cytopathol; 2010 Apr; 118(2):90-6. PubMed ID: 20209622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of membrane localization and aberrant nuclear E-cadherin expression correlates with invasion in pancreatic endocrine tumors.
    Chetty R; Serra S; Asa SL
    Am J Surg Pathol; 2008 Mar; 32(3):413-9. PubMed ID: 18300809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical expression of osteopontin in epithelioid mesotheliomas and reactive mesothelial proliferations.
    Tigrani DY; Weydert JA
    Am J Clin Pathol; 2007 Apr; 127(4):580-4. PubMed ID: 17369133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential expression of galectin-3, beta-catenin, and cyclin D1 in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma of salivary glands.
    Ferrazzo KL; Neto MM; dos Santos E; dos Santos Pinto D; de Sousa SO
    J Oral Pathol Med; 2009 Oct; 38(9):701-7. PubMed ID: 19659475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology.
    Ikeda K; Tate G; Suzuki T; Kitamura T; Mitsuya T
    Hum Pathol; 2010 May; 41(5):745-50. PubMed ID: 20060157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The diagnostic role of claudins in serous effusions.
    Kleinberg L; Holth A; Fridman E; Schwartz I; Shih IeM; Davidson B
    Am J Clin Pathol; 2007 Jun; 127(6):928-37. PubMed ID: 17509990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytologic re-evaluation of negative effusions from patients with malignant mesothelioma.
    Ascoli V; Bosco D; Carnovale Scalzo C
    Pathologica; 2011 Dec; 103(6):318-24. PubMed ID: 22558888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic and prognostic value of Ki67 proliferation fraction in serous effusions.
    Schönherr A; Bayer M; Böcking A
    Cell Oncol; 2004; 26(1-2):57-62. PubMed ID: 15371657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cell adhesion molecule, E-cadherin, distinguishes mesothelial cells from carcinoma cells in fluids.
    Schofield K; D'Aquila T; Rimm DL
    Cancer; 1997 Oct; 81(5):293-8. PubMed ID: 9349517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical detection of XIAP in mesothelium and mesothelial lesions.
    Wu M; Sun Y; Li G; Desman G; Wang B; Gil J; Burstein DE
    Am J Clin Pathol; 2007 Nov; 128(5):783-7. PubMed ID: 17951200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of CD138 (syndecan-1) in distinguishing carcinomas from mesotheliomas.
    Saqi A; Yun SS; Yu GH; Alexis D; Taub RN; Powell CA; Borczuk AC
    Diagn Cytopathol; 2005 Aug; 33(2):65-70. PubMed ID: 16007640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.